(3) New Articles on Potential Breakthroughs in Prostate Cancer!

Hi Guys,

Article #1 deals with targeted therapy for PCa.  They state a new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for prostate cancer.

Article #2 deals with Dr. David Penson, M.D., MPH, professor of Urologic Surgery, “The goal is to find out what works best, in which patients, and in whose hands,” said Penson, the Paul V. Hamilton, M.D. and Virginia E. Howd Professor of Urologic Oncology, who also directs the Vanderbilt Center for Surgical Quality and Outcomes Research.

Article #3 is a very important article for men about to get radiation after diagnosed PCa.  For those of you who were at the May 14th PCa support group meeting, Dr. Kavanaugh discussed this new procedure to protect the rectum during radiation.

1)  Clinical trial tests targeting prostate cancer treatment  (ANN ARBOR, Mich., May 23, 2013)   “The phase 2 trial will look at patients with castration-resistant metastatic prostate cancer, which means the cancer has spread and has stopped responding to hormone-based treatments. The target being evaluated is a genomic rearrangement that causes two genes called TMPRSS2 and ERG to fuse together. This gene fusion, believed to be the triggering event of prostate cancer, was initially discovered in 2005 by U-M researchers led by Arul Chinnaiyan, M.D., Ph.D.”   Full Story 1

2)  VU to lead prostate cancer treatment research effort    (posted: May 23.2013)   Vanderbilt started this network in 2010 through a $7.6 million Agency for Healthcare Research and Quality (AHRQ) grant. Penson’s Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study continues to collect critically important data such as treatment, complications and short-term cancer rates by following nearly 4,000 men diagnosed with prostate cancer”.    Full Story 2

3)  Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer   “As dose-escalation in prostate cancer radiotherapy improves cure rates, a major concern is rectal toxicity. We prospectively assessed an innovative approach of hydrogel injection between prostate and rectum to reduce the radiation dose to the rectum and thus side effects in dose-escalated prostate radiotherapy”.   Full Story 3

God’s Greatest Gift is TIME!

Craig Becker

The New Denver Men’s Club

 University Prostate Cancer Support Group, Inc.
Group Leader



2 thoughts on “(3) New Articles on Potential Breakthroughs in Prostate Cancer!

  1. Good stuff. Thanks for sharing. Wish I was at the beginning of my 15+ year journey. Might have made different decisions. A reason to support research

    • Bob, Most significant PCa breakthroughs have occurred in the last 2 years. We are lucky to be able to take advantage of the new research developments. Your 15 year journey with PCa is remarkable and unheard of just 10 years ago. Going forward, you have many more choices that will change your PCa from terminal to chronic: Provenge, Zytiga, Xtandi, Radium 223, Denosumab, cabazitaxel, and in the pipeline phase III, cabozantinib (already approved for medullary carcinoma of thyroid). Further pipeline drugs include Prostvac, ARN 509, TAK 001, possibly ipilimumab, OGX-011, and capesaris (among many others). Hang in there my friend! Craig

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s